Hamid rana biography templates

Prof Kumar is a founding Co-Director of the pan-university Institute for Sustainability, Professor & Chair in Air Quality and Health, and founding Director of the internationally-leading research centre Global Centre for Clean Air Research (GCARE) at the University of Surrey, UK. He is the founder of successfully running Guildford Living Lab, a Trustee at Zero Carbon Guildford (ZERO), an Adjunct Professor at Trinity College Dublin, Ireland; and a Guest Professor at Southeast University, China.

He joined the Senior Leadership team of the Faculty of Engineering and Physical Sciences as an Associate Dean (International) in 2020 and subsequently took up another senior leadership role to help setup the new pan-University Institute for Sustainability as a founding Co-Director in 2023. As an Associate Dean (International), he worked on implementing the University's Global Strategy and provided leadership to the international agenda, including student recruitment, transforming the PGR international placements through Turing and other mobility schemes, building several successful international research partnerships, coordinated numerous UG and PGT partnerships and joint PhD programmes, and led the QS submission for the University as a 'QS Impact Champion'.

Earlier, he served as a Reader (2015-2017), Senior Lecturer (2012-2015) and Lecturer (2009-2012) before promoting to Chair and Full Professor of Air Quality and Health (2017-) at the University of Surrey. He was the Deputy Director of Research for the Department of Civil & Environmental Engineering during 2018-2021.

An engineer by training, Prof Kumar obtained his PhD (Engineering) from the University of Cambridge (UK) after winning a Cambridge-Nehru Scholarship and Overseas Research Scholarship award. He earned his Master's Degree in Environmental Engineering & Management from the Indian Institute of Technology, Delhi, where he won the ‘Outstanding Postgraduate Student Award’ fo

Abstract

Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is gaining momentum and demonstrating durable responses in patients with advanced melanoma. Although increasingly considered as a treatment option for select patients with melanoma, TIL therapy is not yet approved by any regulatory agency. Pioneering studies with first-generation TIL therapy, undertaken before the advent of modern melanoma therapeutics, demonstrated clinical efficacy and remarkable long-term overall survival, reaching beyond 20 months for responding patients. TIL therapy is a multistep process of harvesting patient-specific tumor-resident T cells from tumors, ex vivo T-cell expansion, and re-infusion into the same patient after a lymphodepleting preparative regimen, with subsequent supportive IL2 administration. Objective response rates between 30% and 50% have consistently been observed in heavily pretreated patients with metastatic melanoma, including those who have progressed after modern immune checkpoint inhibitors and BRAF targeted agents, a population with high unmet medical need. Although significant strides have been made in modern TIL therapeutics, refinement strategies to optimize patient selection, enhance TIL production, and improve efficacy are being explored. Here, we review past and present experience, current challenges, practical considerations, and future aspirations in the evolution of TIL therapy for the treatment of melanoma as well as other solid tumors.

Introduction

In the last decade, the melanoma treatment landscape has dramatically transformed with approvals for immune checkpoint inhibitor (ICI) antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death receptor-1 (PD-1), as well as small-molecule inhibitors targeting the B-Raf proto-oncogene (1, 2). These treatment modalities improve long-term survival of patients and reduce the risk of relapse in the adjuvant setting (3). Unfortunately, despite these advances, m

File:Sonachandi.jpg Nominated for speedy Deletion